Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 10/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453051 | 0.90 | HMGCR (0.48) | HMGCRALDH1A1CYP3A4 | |
| SCHEMBL13637171 | 0.89 | HMGCR (0.47) | HMGCRALDH1A1CYP3A4 | |
| SCHEMBL13637135 | 0.86 | HMGCR (0.46) | HMGCR | |
| SCHEMBL13456278 | 0.86 | HMGCR (0.45) | HMGCR | |
| SCHEMBL11295264 | 0.81 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4 | |
| SCHEMBL4079327 | 0.81 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4 | |
| SCHEMBL1021915 | 0.81 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4 | |
| SCHEMBL1022804 | 0.81 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4 | |
| SCHEMBL4079319 | 0.81 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4 | |
| SCHEMBL4079332 | 0.81 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056783-A1 | Novel Process for the Preparation of Statins and their Pharmaceutically Acceptable Salts thereof | MSN LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056783-A1 | Novel Process for the Preparation of Statins and their Pharmaceutically Acceptable Salts thereof | HMGCR, PCSK9, NPC1L1 | HMGCR 1/4885ALDH1A1 1715/4885CYP3A4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.